Revolutionising cancer care with AI prognosis

The AI-driven tests help doctors select the most effective treatment

Spotted: There is no one-size-fits-all when it comes to cancer treatment. Every patient’s situation is unique, demanding a tailored approach for the best chances of recovery. Spotlight Medical, a pioneering Parisian biotech company, was founded with this in mind.

The startup is using decades of patient data to develop advanced AI tests that will ensure no patient is over- or under-treated – significantly improving cancer outcomes. These tests extract crucial biological information to predict treatment response, helping oncologists choose the best options for their patients. Versatile and secure, the technology adapts to various cancer types, ensuring personalised, effective, and precise care for patients.

“Our incredibly powerful and innovative technology has unlocked unprecedented capabilities in tailoring cancer treatment,” explains Sylvain Berlemont, co-founder and CEO of Spotlight Medical. “The potential impact on patient survival rates and quality of life is immense, heralding a new era in personalised cancer treatment. Our mission is to make it a reality – for patients and their families,” he adds.

Recently, the company has secured a €6.2 million seed funding round led by Kurma Partners and Heal Capital. This investment will help Spotlight Medical to advance its first prognosis test for clinical use, marking a major step forward for AI-driven cancer treatment solutions.

Written By: Georgia King